Latest profit margin for BioMarin Pharmaceutical: -0.52% — see history and peer comparisons.
Get informed when a big investor buys or sells
+ FollowAs of Sep 2026
Trailing 12 months ending Sep 2026
BioMarin Pharmaceutical's profit margin stands at -0.52% as of September 2026. That compares with 16.82% in the prior-year period — down 103.1% year over year. That is below the Healthcare sector average of 17.63%. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.
BioMarin Pharmaceutical reported -0.52% in profit margin versus 16.82% a year earlier — a 103.1% year-over-year decrease. The historical chart on this page makes it easier to see whether that move is part of a longer pattern.
BioMarin Pharmaceutical sits lower the Healthcare benchmark (17.63%) with a profit margin of -0.52%. That is roughly 103.0% below the sector mean. Peer context matters because what looks expensive or cheap in absolute terms can be normal for the sector.
A profit margin of -0.52% for BioMarin Pharmaceutical means each unit of related capital or sales is generating that return rate. Higher is usually better for profitability metrics, but extremely high figures can reflect one-time items or thin equity bases. Review several years of data on this page before extrapolating.
The history chart shows how BioMarin Pharmaceutical's profit margin evolved across reporting periods, while the comparison chart places BM8.F next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.